Physician
Welch, Derek
Welch, Derek was paid $99K by Medicaid between Jan 2018 and Dec 2024, across 13 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 18% of everything it billed.
33Billing provider infoWELCH, DEREK
NASHVILLE, TN 37217
NASHVILLE, TN 37217
33aNPI1093753303assigned 06/02/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$99K
24GClaims10,977
24DCodes billed13
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Tennessee
Rank by total paid#15 of 73
Median peer was paid$13K
This provider vs. median7.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 259 | $1K | |
| 2019 | 462 | $3K | |
| 2020 | 1,942 | $18K | |
| 2021 | 2,720 | $33K | |
| 2022 | 849 | $4K | |
| 2023 | 394 | $4K | |
| 2024incomplete | 4,351 | $36K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 18% | 1,514 | 1,471 | $18K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 18% | 1,507 | 1,464 | $18K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 15% | 401 | 289 | $15K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 11% | 1,107 | 1,074 | $11K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 11% | 1,107 | 1,084 | $11K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 6.2% | 12 | 12 | $6K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 5.6% | 390 | 381 | $6K |
| 87481 | 5.1% | 1,429 | 328 | $5K | |
| 36415 | Collection of venous blood by venipuncture | 3.6% | 1,692 | 1,577 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 3.0% | 1,505 | 279 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.1% | 108 | 98 | $2K |
| 87511 | <1% | 190 | 183 | $508.55 |
1 more codes
| 87653 | <1% | 15 | $503.99 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.